No title
Characterizing the onset and progression of Alzheimer’s disease pathologies relative to one another is important for biological staging and clinical trial design. Recent advances in blood plasma assays of Alzheimer’s disease amyloid and tau pathology have enabled detection of Alzheimer’s disease pathophysiology during life, but it remains unclear when plasma biomarker abnormalities are detectable
